# HealthCare Ventures

> HealthCare Ventures is a VC fund backing Biotechnology and Health Care. See 103 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Cambridge, United States
- Total investments: 103
- Last investment: Sep 2020
- Lead investor: 17%
- Fund size: $250M
- Last fund: Jan 2010
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/healthcare-ventures-llc
- Website: http://www.hcven.com

HealthCare Ventures is a leading life science venture capital firm investing in pre-clinical or early clinical stage, focused companies with potential to transform patient care.

## Contacts

5 contacts available for HealthCare Ventures. Shizune tracks 7 team members at HealthCare Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/healthcare-ventures?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $4.4M–$37M |
| Series B | $10M–$50M |
| Series C | $15M–$44M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 47 | 46% |
| Health Care | 34 | 33% |
| Pharmaceutical | 22 | 21% |
| Medical | 20 | 19% |
| Therapeutics | 14 | 14% |

31 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 27 | 26% |
| Series A | 22 | 21% |
| Series C | 10 | 10% |
| Funding Round | 9 | 9% |
| Series D | 7 | 7% |

11 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 51 | 50% |
| Australia | 1 | 1% |
| United Kingdom | 1 | 1% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| John Littlechild | Managing Director & General Partner | 0 | https://shizune.co/investors/profile/john-w-littlechild |
| Christopher K. Mirabelli | Managing Director | 11 | https://shizune.co/investors/profile/christopher-k-mirabelli |
| Douglas E. Onsi | Managing Director | 1 | https://shizune.co/investors/profile/douglas-e-onsi |
| Harold Werner | Co-Founder & Managing Director | 5 | https://shizune.co/investors/profile/harold-r-werner |
| James H. Cavanaugh | Managing Director | 3 | https://shizune.co/investors/profile/james-h-cavanaugh |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Colorescience | Colorescience is a luxury aesthetic makeup line in the medical and resort spa channel, differentiating their products from other makeup lines through high quality, efficacious ingredients, luxury colores and formulations, and convenience and simplicity of use. With every product the company strives to make a difference in the diminution of skincancer and skin conditions. | $30M | Debt Financing | Sep 14, 2020 |  |
| Leap Therapeutics | Leap Therapeutics, Inc., a clinical-stage biopharmaceutical company, is engaged in acquiring and developing novel therapeutics. The company focus is to identify translational-stage molecules in the areas of cell signaling and immuno-oncology. |  |  | Jan 01, 2016 |  |
| Proteostasis Therapeutics | Proteostasis Therapeutics is discovering and developing novel small molecule therapeutics designed to control the body's protein homeostasis, or Proteostasis Network. The Proteostasis Network maintains the body's natural balance of proteins to protect us from numerous diseases. These novel therapies, or Proteostasis Regulators, aredesigned to treat multiple genetic and degenerative disorders associated with deficiencies of the Proteostasis Network, such as emphysema, type II diabetes, Alzheimer's Disease and Huntington's Disease. | $37M | Series B | Sep 08, 2015 |  |
| Galleon Pharmaceuticals | Galleon Pharmaceuticals engages in the discovery and development of medicines for breathing-control conditions in the United States. It focuses on developing a portfolio of therapeutics for the treatment of sleep apnea, ventilator weaning, anesthetic/analgesic-induced respiratory depression, COPD, obesity-hypoventilation syndrome, and othercommon diseases. The company was incorporated in 2003 and is based in Horsham, Pennsylvania. | $10M | Series B | Jun 11, 2015 |  |
| Vaxxas | Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia. | $25M | Series B | Feb 10, 2015 |  |
| Colorescience | Colorescience is a luxury aesthetic makeup line in the medical and resort spa channel, differentiating their products from other makeup lines through high quality, efficacious ingredients, luxury colores and formulations, and convenience and simplicity of use. With every product the company strives to make a difference in the diminution of skincancer and skin conditions. | $15M | Series B | Sep 10, 2014 |  |
| Senseonics | Senseonics is a medical device startup company in Germantown, Maryland, USA (near Washington, DC) developing transformative glucose monitoring products that is intended to enable people with diabetes to confidently live their lives with ease. Utilizing breakthrough fluorescence sensing technology, the Senseonics continuous glucose monitoring("CGM") system is being designed to be the first fully implantable CGM that is highly accurate and stable throughout its long sensor life. | $20M |  | Jun 05, 2014 |  |
| Pathogenetix | PathoGenetiX is developing an automated system for the rapid identification of pathogenic bacterial strains using proprietary Genome Sequence Scanning Technology. The company's approach, which employs a single reagent set to generate genomic bar codes based on bacterial DNA, can cost-effectively identify thousands of strains in a single testfrom complex samples in three hours. PathoGenetiX is developing its GSS platform for use in genomics research, food and product safety testing, and clinical infectious disease diagnostics, with the initial commercial introduction into the research market planned for 2012. |  | Series C | Oct 30, 2013 |  |
| Gyre Therapeutics | Catalyst Biosciences is a drug discovery and development company. It is creating novel catalytic biopharmaceutical products based on engineered human proteases. The mission is to establish protease therapeutics as a new therapeutic platform comparable in depth and scope to antibody pharmaceuticals. The Company is developing proteases for thetreatment of a broad range of diseases with a strong focus on hemostasis and inflammation. Founded in 1997, the company is headquartered in South San Francisco, California. |  | Post-IPO Equity | Apr 01, 2013 |  |
| Theraclone Sciences | Theraclone Sciences (formerly Spaltudaq) is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company's technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cellsof immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment. | $8M | Series B | Mar 25, 2013 |  |

10 of 103 investments shown.

## Co-investors
- [Oxford Bioscience Partners](https://shizune.co/investors/profile/oxford-bioscience-partners) — VC Fund, 13 deals together
- [MPM Capital](https://shizune.co/investors/profile/mpm-capital) — VC Fund, 12 deals together
- [Morgenthaler Ventures](https://shizune.co/investors/profile/morgenthaler-ventures) — VC Fund, 10 deals together
- [Amgen Ventures](https://shizune.co/investors/profile/amgen-ventures) — VC Fund, 9 deals together
- [Rho Ventures](https://shizune.co/investors/profile/rho-ventures) — VC Fund, 8 deals together
- [Johnson & Johnson Development Corporation](https://shizune.co/investors/profile/johnson-johnson-development-corporation) — VC Fund, 7 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Artesian VC](https://shizune.co/investors/profile/artesian-capital-management) — VC Fund
- [Blackbird Ventures](https://shizune.co/investors/profile/blackbird-ventures-australia) — VC Fund

## Featured in investor lists
- [Biotech VC Funds](https://shizune.co/investors/biotech-vc-funds)
- [Biotech Investors in United States](https://shizune.co/investors/biotech-investors-united-states)
- [Biotech VC Funds in United States](https://shizune.co/investors/biotech-vc-funds-united-states)
- [Biotech Investors in Australia](https://shizune.co/investors/biotech-investors-australia)
- [Biotech VC Funds in Australia](https://shizune.co/investors/biotech-vc-funds-australia)
- [Health Care VC Funds in Australia](https://shizune.co/investors/health-care-vc-funds-australia)

## FAQ

### What does HealthCare Ventures invest in?

HealthCare Ventures invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series B and Series A stage. Most of the 103 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is HealthCare Ventures's check size?

HealthCare Ventures typically joins rounds of $4.4M–$37M at Series A, $10M–$50M at Series B and $15M–$44M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds HealthCare Ventures participates in.

### How do I contact HealthCare Ventures?

Public channels for HealthCare Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at HealthCare Ventures?

The team at HealthCare Ventures includes John Littlechild (Managing Director & General Partner), Christopher K. Mirabelli (Managing Director) and Douglas E. Onsi (Managing Director), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co